ATE365210T1 - Glykosylierte proteine mit reduzierter allergenität - Google Patents

Glykosylierte proteine mit reduzierter allergenität

Info

Publication number
ATE365210T1
ATE365210T1 AT99947259T AT99947259T ATE365210T1 AT E365210 T1 ATE365210 T1 AT E365210T1 AT 99947259 T AT99947259 T AT 99947259T AT 99947259 T AT99947259 T AT 99947259T AT E365210 T1 ATE365210 T1 AT E365210T1
Authority
AT
Austria
Prior art keywords
allergenity
reduced
glycosylated proteins
proteins
allergenicity
Prior art date
Application number
AT99947259T
Other languages
English (en)
Inventor
Arne Olsen
Erwin Roggen
Steffen Ernst
Original Assignee
Novozymes As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novozymes As filed Critical Novozymes As
Application granted granted Critical
Publication of ATE365210T1 publication Critical patent/ATE365210T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01003—Triacylglycerol lipase (3.1.1.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
AT99947259T 1998-10-30 1999-10-12 Glykosylierte proteine mit reduzierter allergenität ATE365210T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA199801401 1998-10-30
DKPA199801551 1998-11-25
DKPA199900682 1999-05-17
DKPA199901419 1999-10-04

Publications (1)

Publication Number Publication Date
ATE365210T1 true ATE365210T1 (de) 2007-07-15

Family

ID=27439358

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99947259T ATE365210T1 (de) 1998-10-30 1999-10-12 Glykosylierte proteine mit reduzierter allergenität

Country Status (9)

Country Link
EP (1) EP1124946B1 (de)
JP (1) JP2002531067A (de)
CN (1) CN1325443A (de)
AT (1) ATE365210T1 (de)
AU (1) AU774156B2 (de)
CA (1) CA2348822A1 (de)
DE (1) DE69936351T2 (de)
ES (1) ES2289824T3 (de)
WO (1) WO2000026354A1 (de)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US7378506B2 (en) 1997-07-21 2008-05-27 Ohio University Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
US6639050B1 (en) 1997-07-21 2003-10-28 Ohio University Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
US6747003B1 (en) 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7431921B2 (en) 2000-04-14 2008-10-07 Maxygen Aps Interferon beta-like molecules
US7144574B2 (en) 1999-08-27 2006-12-05 Maxygen Aps Interferon β variants and conjugates
US6531122B1 (en) 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
US6806063B2 (en) 2000-02-11 2004-10-19 Maxygen Aps Factor VII or VIIa-like molecules
US7220837B1 (en) 2000-04-28 2007-05-22 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7812132B2 (en) 2000-04-28 2010-10-12 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US20030211094A1 (en) 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
US6933367B2 (en) 2000-10-18 2005-08-23 Maxygen Aps Protein C or activated protein C-like molecules
SK11882003A3 (sk) 2001-02-27 2004-03-02 Maxygen Aps Variant štandardného ľudského interferónu ß, nukleotidová sekvencia kódujúca tento variant, expresný vektor a hostiteľská bunka s jej obsahom, farmaceutický prostriedok s obsahom uvedeného variantu a jeho použitie
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US8008252B2 (en) 2001-10-10 2011-08-30 Novo Nordisk A/S Factor VII: remodeling and glycoconjugation of Factor VII
US7696163B2 (en) 2001-10-10 2010-04-13 Novo Nordisk A/S Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7795210B2 (en) 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
JP5424521B2 (ja) 2001-12-21 2014-02-26 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド アルブミン融合タンパク質
ES2377519T3 (es) 2002-02-08 2012-03-28 Novozymes A/S Variantes de fitasa
PT1499719E (pt) 2002-04-30 2011-02-09 Bayer Healthcare Llc Variantes polipeptídicas do factor vii ou viia
US7943763B2 (en) * 2002-07-05 2011-05-17 Otsuka Chemical Holdings Co., Ltd. Process for preparing glycopeptides having asparagine-linked oligosaccharides, and the glycopeptides
WO2004031378A2 (en) 2002-10-01 2004-04-15 Novozymes A/S Family gh 61 polypeptides
MXPA05009726A (es) 2003-03-14 2005-11-04 Neose Technologies Inc Polimeros ramificados, solubles en agua y sus conjugados.
EP2085470B1 (de) 2003-03-20 2012-05-16 Bayer HealthCare LLC FVII oder FVIIa Varianten
EP1615945B1 (de) 2003-04-09 2011-09-28 BioGeneriX AG Glycopegylierungsverfahren und durch die verfahren hergestellte proteine/peptide
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
ATE540055T1 (de) 2003-05-09 2012-01-15 Biogenerix Ag Zusammensetzungen und verfahren zur herstellung von glykosylierungsmutanten des menschlichen wachstumshormons
NZ573412A (en) 2003-06-19 2010-09-30 Maxygen Holdings Ltd Factor VII or VIIa Gla domain variants
CN1809634A (zh) 2003-06-19 2006-07-26 诺维信公司 蛋白酶
US20060236414A1 (en) 2003-06-19 2006-10-19 Novozymes A/S Proteases and methods for producing them
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
WO2005035747A1 (en) 2003-10-10 2005-04-21 Novozymes A/S Protease variants
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US7842661B2 (en) 2003-11-24 2010-11-30 Novo Nordisk A/S Glycopegylated erythropoietin formulations
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US7956032B2 (en) 2003-12-03 2011-06-07 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
JP5059412B2 (ja) 2004-01-06 2012-10-24 ノボザイムス アクティーゼルスカブ アリシクロバシラスｓｐ．のポリペプチド
JP5743368B2 (ja) 2004-01-08 2015-07-01 ラショファーム ゲーエムベーハー ペプチドのｏ結合型グリコシル化
MXPA06008126A (es) 2004-01-14 2008-02-14 Univ Ohio Metodos para la produccion de peptidos/proteinas en plantas y peptidos/proteinas producidos de este modo.
EP1718664A4 (de) 2004-02-02 2008-08-13 Ambrx Inc Modifizierte menschliche vierhelix-bündel-peptide und ihre verwendungen
US8623812B2 (en) 2004-04-19 2014-01-07 Ohio University Cross-linkable glycoproteins and methods of making the same
US20070225207A1 (en) * 2004-04-23 2007-09-27 Novozymes A/S Group 1 Mite Polypeptide Variants
KR101699142B1 (ko) 2004-06-18 2017-01-23 암브룩스, 인코포레이티드 신규 항원-결합 폴리펩티드 및 이의 용도
MXPA06014649A (es) 2004-06-21 2007-03-12 Novozymes As Proteasas.
EP1771066A2 (de) 2004-07-13 2007-04-11 Neose Technologies, Inc. Remodellierung von verzweigtem peg und klykolysierung von glucagonähnlichem peptide-1 glp-1
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
US8268967B2 (en) 2004-09-10 2012-09-18 Novo Nordisk A/S Glycopegylated interferon α
BRPI0517539A (pt) 2004-10-04 2008-10-14 Novozymes As polipeptìdeo isolado, polinucleotìdeo isolado, construto de ácido nucleico, vetor de expressão recombinante, célula hospedeira recombinante, métodos para produzir o polipeptìdeo, e para melhorar o valor nutricional de uma ração animal, célula de planta, parte de planta ou planta transgênica, animal não-humano, transgênico, ou produtos, ou elementos do mesmo, uso de pelo menos um polipeptìdeo, aditivo de ração animal, e, composição de ração animal
AR050895A1 (es) 2004-10-04 2006-11-29 Novozymes As Polipeptidos que tienen actividad de fitasa y polinucleotidos que los codifican
EP1814573B1 (de) 2004-10-29 2016-03-09 ratiopharm GmbH Remodellierung und glykopegylierung von fibroblasten-wachstumsfaktor (fgf)
ATE541934T1 (de) 2004-12-22 2012-02-15 Ambrx Inc Zusammensetzungen von aminoacyl-trna-synthetase und verwendungen davon
US7939496B2 (en) 2004-12-22 2011-05-10 Ambrx, Inc. Modified human growth horomone polypeptides and their uses
BRPI0519170A8 (pt) 2004-12-22 2018-05-08 Ambrx Inc formulações de hormônio de crescimento humano que compreendem um aminoácido não naturalmente codificado
US8080391B2 (en) 2004-12-22 2011-12-20 Ambrx, Inc. Process of producing non-naturally encoded amino acid containing high conjugated to a water soluble polymer
MX2007008229A (es) 2005-01-10 2007-09-11 Neose Technologies Inc Factor estimulador de colonias de granulocitos glicopegilado.
US9187546B2 (en) 2005-04-08 2015-11-17 Novo Nordisk A/S Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
JP5216580B2 (ja) 2005-05-25 2013-06-19 ノヴォ ノルディスク アー／エス グリコペグ化第ｉｘ因子
CN101247821B (zh) 2005-06-03 2013-01-23 Ambrx公司 经改良人类干扰素分子和其用途
EP2360246A1 (de) 2005-08-16 2011-08-24 Novozymes A/S Polypeptide von Stammbakterien SP P203
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
CN106443006A (zh) 2005-11-16 2017-02-22 Ambrx公司 包括非天然氨基酸的方法和组合物
WO2007107573A1 (en) 2006-03-22 2007-09-27 Novozymes A/S Use of polypeptides having antimicrobial activity
EP2001999B1 (de) 2006-04-04 2012-05-16 Novozymes A/S Phytasevarianten
CN101516388B (zh) 2006-07-21 2012-10-31 诺和诺德公司 通过o-联糖基化序列的肽的糖基化
MX2009002523A (es) 2006-09-08 2009-03-20 Ambrx Inc Polipeptido de plasma humano modificado o andamios fc y sus usos.
DK2064333T3 (da) 2006-09-08 2014-05-05 Ambrx Inc Suppressor-trna-transkription i hvirveldyrceller
US20100075375A1 (en) 2006-10-03 2010-03-25 Novo Nordisk A/S Methods for the purification of polypeptide conjugates
EP2261328B1 (de) 2006-12-21 2013-11-20 Novozymes A/S Lipase-varianten zur pharmazeutischen Verwendung
US8221743B2 (en) 2006-12-22 2012-07-17 Novozymes A/S Use of polypeptides against diseases caused by protozoans
DK2129781T3 (da) 2007-03-26 2014-03-31 Novozymes As Hafnia-phytase
KR20140012199A (ko) 2007-03-30 2014-01-29 암브룩스, 인코포레이티드 변형된 ｆｇｆ-21 폴리펩티드 및 그 용도
PL2144923T3 (pl) 2007-04-03 2013-12-31 Biogenerix Ag Sposoby leczenia z użyciem glikopegilowanego G-CSF
JP2010525821A (ja) 2007-05-02 2010-07-29 アンブルックス，インコーポレイテッド 修飾ＩＦＮβポリペプチドおよびこれらの使用
EP2170919B8 (de) 2007-06-12 2016-01-20 ratiopharm GmbH Verbessertes verfahren zur herstellung von nukleotidzuckern
US8207112B2 (en) 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate
KR101656107B1 (ko) 2007-11-20 2016-09-08 암브룩스, 인코포레이티드 변형된 인슐린 폴리펩티드 및 이의 용도
NZ602170A (en) 2008-02-08 2014-03-28 Ambrx Inc Modified leptin polypeptides and their uses
DK2257311T3 (da) 2008-02-27 2014-06-30 Novo Nordisk As Konjugerede Faktor VIII-Molekyler
CA2729851C (en) 2008-07-23 2019-01-15 Ambrx, Inc. Modified bovine g-csf polypeptides and their uses
EP2342323B1 (de) 2008-09-26 2013-06-05 Novozymes A/S Hafnia-phytasevarianten
CN107022020A (zh) 2008-09-26 2017-08-08 Ambrx公司 修饰的动物促红细胞生成素多肽和其用途
US9121024B2 (en) 2008-09-26 2015-09-01 Ambrx, Inc. Non-natural amino acid replication-dependent microorganisms and vaccines
CN104017063A (zh) 2009-12-21 2014-09-03 Ambrx公司 经过修饰的猪促生长素多肽和其用途
CN107674121A (zh) 2009-12-21 2018-02-09 Ambrx 公司 经过修饰的牛促生长素多肽和其用途
WO2011123505A1 (en) * 2010-03-30 2011-10-06 Novozymes North America, Inc. Processes of producing a fermentation product
WO2011133948A2 (en) 2010-04-22 2011-10-27 Longevity Biotech, Inc. Highly active polypeptides and methods of making and using the same
EP3572091B1 (de) 2010-08-17 2023-12-13 Ambrx, Inc. Modifizierte relaxinpolypeptide und deren verwendungen
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
AR083006A1 (es) 2010-09-23 2013-01-23 Lilly Co Eli Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas
JP5808559B2 (ja) 2011-03-31 2015-11-10 独立行政法人石油天然ガス・金属鉱物資源機構 炭化水素油の製造方法、フィッシャー・トロプシュ合成反応装置及び炭化水素油の製造システム
US9790262B2 (en) 2011-04-05 2017-10-17 Longevity Biotech, Inc. Compositions comprising glucagon analogs and methods of making and using the same
US9789164B2 (en) 2013-03-15 2017-10-17 Longevity Biotech, Inc. Peptides comprising non-natural amino acids and methods of making and using the same
TWI705071B (zh) 2014-10-24 2020-09-21 美商必治妥美雅史谷比公司 經修飾之fgf-21多肽及其用途
IL258759B2 (en) 2015-11-03 2023-04-01 Ambrx Inc Anti-cd3-folate conjugates and their uses
SG10201912034UA (en) 2017-02-08 2020-02-27 Bristol Myers Squibb Co Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
CA3072903A1 (en) 2017-09-08 2019-03-14 Bristol-Myers Squibb Company Modified fibroblast growth factor 21 (fgf-21) for use in methods for treating nonalcoholic steatohepatitis (nash)
WO2020010117A2 (en) 2018-07-03 2020-01-09 Bristol-Myers Squibb Company Fgf21 formulations
JP2021535140A (ja) 2018-08-28 2021-12-16 アンブルックス, インコーポレイテッドAmbrx, Inc. 抗ｃｄ３抗体葉酸生物複合体およびその使用
WO2020096958A1 (en) 2018-11-05 2020-05-14 Bristol-Myers Squibb Company Method for purifying pegylated protein
WO2021173889A1 (en) 2020-02-26 2021-09-02 Ambrx, Inc. Uses of anti-cd3 antibody folate bioconjugates
PE20231568A1 (es) 2020-08-13 2023-10-04 Novozymes As Variantes de fitasa y polinucleotidos que codifican las mismas

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8621118D0 (en) * 1986-09-01 1986-10-08 Whitbread & Co Plc Stabilised polypeptides
US5041376A (en) * 1988-12-09 1991-08-20 The Board Of Regents Of The University Of Texas System Method for identifying or shielding functional sites or epitopes of proteins that enter the exocytotic pathway of eukaryotic cells, the mutant proteins so produced and genes encoding said mutant proteins
US5766897A (en) * 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US5585250A (en) * 1993-08-20 1996-12-17 The United States Of America As Represented By The Department Of Health & Human Services Dampening of an immunodominant epitope of an antigen for use in plant, animal and human compositions and immunotherapies
GB9517494D0 (en) * 1995-08-25 1995-10-25 Mini Agriculture & Fisheries Recominent DNA expression system

Also Published As

Publication number Publication date
JP2002531067A (ja) 2002-09-24
EP1124946A1 (de) 2001-08-22
DE69936351D1 (de) 2007-08-02
CA2348822A1 (en) 2000-05-11
WO2000026354A1 (en) 2000-05-11
DE69936351T2 (de) 2008-02-21
EP1124946B1 (de) 2007-06-20
AU774156B2 (en) 2004-06-17
CN1325443A (zh) 2001-12-05
AU6078699A (en) 2000-05-22
ES2289824T3 (es) 2008-02-01

Similar Documents

Publication Publication Date Title
DE69936351D1 (de) Glykosylierte proteine mit reduzierter allergenität
NO2017027I1 (no) efmoroctocog alfa eller et biotilsvarende legemiddel ihht Artikkel 10(4) av Directive 2001/83/EC, som beskyttet av basispatentet.
YU9404A (sh) Multimerna, usmerena kontrastna sredstva na bazi peptida
PL374178A1 (en) Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
BR0215405A (pt) Composições e processos de uso de collajolie
BR0113798A (pt) Derivados de resorcinol
MXPA03007323A (es) Proteinas artificiales con inmunogenicidad reducida.
BR0204884B1 (pt) montagem de coxim de cisalhamento.
ATE347057T1 (de) Federelement
ATE330017T1 (de) Kallikrein gen
BR0201919B1 (pt) colheitadeira.
CA97633S (en) Trimmer
ITRM20010044A0 (it) Integratore alimentare ad effetto dimagrante.
WO2002010752A3 (de) Sensor-chips mit polysiloxan-mehrfachschichten
AU2001291532A1 (en) Lighting device
MY141606A (en) N-alkoxyalkyl-substituted benzimidazoles, their preparation and their use as agents against parasitic protozoa
DE50110117D1 (de) Lineare Polydialkylorganosiloxane mit Polyoxyalkylen- und aminofunktionellen Gruppen, die zusätzlich endständige Alkoxygruppen aufweisen
AU2003259750A1 (en) Methods and compositions for targeting secretory lysosomes
ES2192034T3 (es) Feniluracilos substituidos con efecto herbicida.
DE59805182D1 (de) Schaltung mit Pumpstützdrossel, zur Verbesserung des Leistungsfaktors
BR0315222A (pt) Promotor de il-18bp, sua preparação e uso
ITMI20022028A1 (it) Fenton i.s.
ITMI20021205A1 (it) Uso di proteine per il trattamento della leishmaniosi
DE60117001D1 (de) Nectin-3 proteine
MY142798A (en) Methods for preventing glyconoylation of proteins

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties